Robocap Asset Management Ltd Increases Holdings in PROCEPT BioRobotics Corporation $PRCT

Robocap Asset Management Ltd grew its holdings in PROCEPT BioRobotics Corporation (NASDAQ:PRCT) by 32.1% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 138,840 shares of the company’s stock after buying an additional 33,760 shares during the quarter. PROCEPT BioRobotics makes up about 3.2% of Robocap Asset Management Ltd’s investment portfolio, making the stock its 18th largest holding. Robocap Asset Management Ltd owned approximately 0.25% of PROCEPT BioRobotics worth $4,955,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. JTC Employer Solutions Trustee Ltd bought a new position in shares of PROCEPT BioRobotics during the third quarter valued at approximately $30,000. Vega Investment Solutions increased its position in PROCEPT BioRobotics by 52.0% during the 2nd quarter. Vega Investment Solutions now owns 775 shares of the company’s stock valued at $45,000 after purchasing an additional 265 shares during the period. AlphaQuest LLC raised its holdings in PROCEPT BioRobotics by 1,262.5% in the 2nd quarter. AlphaQuest LLC now owns 1,090 shares of the company’s stock worth $63,000 after purchasing an additional 1,010 shares in the last quarter. CWM LLC lifted its position in shares of PROCEPT BioRobotics by 40.7% in the 2nd quarter. CWM LLC now owns 1,228 shares of the company’s stock worth $71,000 after purchasing an additional 355 shares during the period. Finally, Lazard Asset Management LLC lifted its position in shares of PROCEPT BioRobotics by 90.7% in the 2nd quarter. Lazard Asset Management LLC now owns 1,703 shares of the company’s stock worth $98,000 after purchasing an additional 810 shares during the period. 89.46% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on PRCT shares. UBS Group assumed coverage on shares of PROCEPT BioRobotics in a research note on Friday, December 12th. They issued a “buy” rating and a $62.00 price target for the company. Leerink Partners reissued an “outperform” rating and issued a $55.00 target price on shares of PROCEPT BioRobotics in a research report on Wednesday, November 5th. TD Cowen lowered their target price on PROCEPT BioRobotics from $85.00 to $50.00 and set a “buy” rating for the company in a research note on Wednesday, November 5th. Morgan Stanley reduced their price target on PROCEPT BioRobotics from $56.00 to $51.00 and set an “overweight” rating on the stock in a research note on Tuesday, December 2nd. Finally, Wells Fargo & Company lowered their price objective on PROCEPT BioRobotics from $58.00 to $51.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $53.40.

PROCEPT BioRobotics Stock Performance

PROCEPT BioRobotics stock opened at $29.13 on Friday. PROCEPT BioRobotics Corporation has a twelve month low of $27.80 and a twelve month high of $76.40. The company has a quick ratio of 7.20, a current ratio of 8.44 and a debt-to-equity ratio of 0.14. The company has a market capitalization of $1.63 billion, a P/E ratio of -19.04 and a beta of 0.99. The stock’s 50 day moving average is $32.19 and its 200 day moving average is $37.76.

PROCEPT BioRobotics (NASDAQ:PRCT) last released its earnings results on Tuesday, November 4th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.03. PROCEPT BioRobotics had a negative return on equity of 21.72% and a negative net margin of 28.20%.The business had revenue of $83.33 million for the quarter, compared to the consensus estimate of $80.78 million. During the same period in the previous year, the company posted ($0.40) earnings per share. The company’s revenue for the quarter was up 42.6% compared to the same quarter last year. On average, equities research analysts predict that PROCEPT BioRobotics Corporation will post -1.75 earnings per share for the current fiscal year.

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.